Provided by Tiger Trade Technology Pte. Ltd.

Gilead Sciences

143.72
-1.0900-0.75%
Post-market: 143.58-0.1428-0.10%19:30 EDT
Volume:4.20M
Turnover:605.07M
Market Cap:178.31B
PE:-54.96
High:145.99
Open:145.24
Low:143.50
Close:144.81
52wk High:157.29
52wk Low:108.46
Shares:1.24B
Float Shares:1.24B
Volume Ratio:0.77
T/O Rate:0.34%
Dividend:3.22
Dividend Rate:2.24%
EPS(TTM):-2.6150
EPS(LYR):6.78
ROE:-20.68%
ROA:14.09%
PB:15.07
PE(LYR):21.20

Loading ...

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Danaher (DHR) and Henry Schein (HSIC)

TIPRANKS
·
Aug 04

Rani Therapeutics Names Michelle Gilson to Board as Audit Committee Chair

Reuters
·
Aug 04

Gilead update on California ruling removes an overhang, says UBS

TIPRANKS
·
Aug 04

California Supreme Court Rules for Gilead in TDF Litigation

Reuters
·
Aug 04

California Supreme Court Rules in Favor of Gilead Sciences in 'Duty to Innovate' Case Involving Hiv Drugs

THOMSON REUTERS
·
Aug 04

Gilead’s GS-2426 Phase 1 Trial Targets MTAP-Deleted Tumors: What Investors Should Know

TIPRANKS
·
Aug 04

Eli Lilly Could Swing Over $76 Billion In Value After Earnings

Benzinga_recent_news
·
Aug 03

Compugen Publishes Corporate Presentation on AI-Driven Immuno-Oncology Antibody Pipeline

Reuters
·
Aug 03

Israel's Compugen Q2 Revenue More than Doubles, Net Loss Narrows

Reuters
·
Aug 03

Compugen Q2 FY26 Net Loss Narrows to USD 7 Million; Revenue More than Doubled to USD 2.6 Million

Reuters
·
Aug 03

Moderna Inc. Stock Slips 5.4%, Underperforms Peers

Dow Jones
·
Aug 01

Gilead Sciences Inc. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Jul 31

Gilead’s Twice-Yearly HIV Strategy: What the New Phase 3 Study Means for Investors

TIPRANKS
·
Jul 31

Movement Alert|Gilead Sciences Falls 3.02% in Regular Trading, Biotech Sector Broad Selloff Triggers Technical Pullback

Market Focus
·
Jul 30

Analysts Conflicted on These Healthcare Names: Biogen (BIIB), NeuroPace (NPCE) and Gilead Sciences (GILD)

TIPRANKS
·
Jul 30

Gilead price target lowered to $145 from $155 at Barclays

TIPRANKS
·
Jul 29

Movement Alert|Gilead Sciences Overnight Rise 3.46%, Earnings Expectations and Oncology Pipeline Catalysts Drive Momentum

Market Focus
·
Jul 29

Earning Preview: Gilead Sciences revenue is expected to increase by 6.13%, and institutional views are bullish

Earnings Agent
·
Jul 29

Gilead Sciences Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Jul 29

Movement Alert|Gilead Sciences Rises 3.13% in Regular Trading, Biotech Sector Rally and Earnings Optimism Fuel Gains

Market Focus
·
Jul 28